Cagrilintide

What Is Cagrilintide?

Cagrilintide is a long‑acting amylin analog developed by Novo Nordisk as a synthetic derivative of the pancreatic hormone amylin (islet amyloid polypeptide), engineered for once‑weekly subcutaneous dosing. It is being investigated for weight loss, appetite regulation, and glycemic control in obesity and type 2 diabetes across a series of phase 2 and phase 3 programs. As of May 2026, cagrilintide remains investigational and is not approved as a stand‑alone therapy by the FDA, EMA, TGA, or other major regulators.

The compound incorporates structural modifications (including N‑terminal lipidation and selected amino acid substitutions) that extend plasma stability and prolong amylin receptor activation, enabling once‑weekly dosing. Cagrilintide signals via amylin receptors formed by the calcitonin receptor and receptor activity‑modifying proteins (CALCR/RAMP complexes), providing a mechanism distinct from GLP‑1 receptor agonists and complementary to agents such as semaglutide.

Current clinical development explores cagrilintide as monotherapy and as part of the fixed‑dose CagriSema combination (cagrilintide 2.4 mg plus semaglutide 2.4 mg), with primary endpoints focused on body weight, appetite, glycemic measures, and longer‑term metabolic outcomes. CagriSema has completed pivotal phase 3 trials (REDEFINE program) and has submitted a New Drug Application to the FDA, but no marketing authorization has been granted as of this writing.

Mechanism of Action

Cagrilintide primarily activates amylin receptors in key appetite‑regulating regions of the brain, including the area postrema and dorsal vagal complex, via heterodimeric receptor complexes containing the calcitonin receptor and RAMP proteins (AMY1–3 receptors).

One of its most characterized peripheral actions is delayed gastric emptying, which prolongs post‑meal fullness and may reduce caloric intake. Amylin‑pathway activation also suppresses postprandial glucagon secretion, complementing GLP‑1–mediated effects on insulin secretion and glucose control without directly stimulating insulin release.

Preclinical and translational work suggests cagrilintide influences both homeostatic nuclei (area postrema, nucleus tractus solitarius) and hedonic circuits (such as the lateral parabrachial area and downstream reward‑related structures), supporting reductions in food cravings and energy intake.

Pharmacokinetic data from phase 1 trials indicate a half‑life of approximately 159–195 hours (around 7–8 days), with once‑weekly subcutaneous administration producing relatively stable plasma levels. This extended half‑life underpins its use in long‑term lifestyle and metabolic protocols under investigational settings.

Cagrilintide Benefits

Evidence for cagrilintide’s benefits comes primarily from phase 2 trials and emerging phase 3 data in populations with obesity (with and without type 2 diabetes). These data support clinically meaningful effects on appetite regulation, weight reduction, and metabolic parameters. However, the compound remains investigational.

Weight Reduction as Monotherapy

In a multicenter phase 2 trial, once‑weekly cagrilintide at doses of 0.3-4.5 mg produced dose‑dependent weight loss over 26 weeks in adults with overweight/obesity without diabetes, on top of lifestyle intervention. The highest tested dose (4.5 mg) achieved a mean weight reduction of about 10.8% (≈11.5 kg) versus 3.0% with placebo and 9.0% with liraglutide 3.0 mg daily.

A post‑hoc phase 3 analysis from REDEFINE‑1 reported that cagrilintide 2.4 mg monotherapy achieved a mean body‑weight reduction of roughly 11.8% at 68 weeks (trial‑product estimand), compared with about 2.3-3.0% with placebo, further supporting its potential as an amylin‑based monotherapy for obesity.

Combination Therapy: CagriSema

The cagrilintide-semaglutide fixed‑dose combination (CagriSema, 2.4 mg/2.4 mg once weekly) has shown greater weight loss than either component alone in both early‑stage and phase 3 studies.

• In an earlier phase 1b trial, adding escalating cagrilintide (up to 2.4 mg) to semaglutide 2.4 mg yielded a mean weight reduction of about 17.1% at 20 weeks, compared with about 9.8% for semaglutide alone.
• In a phase 2 trial in adults with type 2 diabetes and overweight/obesity, CagriSema resulted in a mean weight loss of approximately 15.6% at 32 weeks, compared with 8.1% for cagrilintide alone and 5.1% for semaglutide alone.
• Phase 3 REDEFINE‑1 and REDEFINE‑2 data in adults with obesity or overweight show mean weight reductions around 20–23% with CagriSema at 68–84 weeks, depending on the analytic framework, compared with roughly 3% for placebo, 11–12% for cagrilintide alone, and 15–16% for semaglutide alone.

Given these results, it is more accurate to describe CagriSema as achieving approximately 15–17% weight loss in early trials and around 20–23% in phase 3 rather than “~25%” mean loss. A meaningful subset of participants, however, do reach ≥25% weight reduction at 68 weeks.

Glycemic Control

In people with type 2 diabetes, CagriSema has produced larger HbA1c reductions than cagrilintide alone and numerically greater reductions than semaglutide alone, while further improving fasting and postprandial glucose. Cagrilintide monotherapy has more modest glycemic effects in non‑diabetic obesity populations but still improves triglycerides, VLDL, waist circumference, and eating‑behavior scores.

Ongoing and upcoming phase 3 programs (REDEFINE and the planned RENEW monotherapy program) will better define long‑term metabolic and safety outcomes, but no dedicated cardiovascular outcomes trial has yet been completed.

Complementary Appetite Regulation

The combination of amylin and GLP-1 receptor activation targets appetite regulation through distinct central and peripheral mechanisms. Researchers believe that activation of these complementary pathways may contribute to additive efficacy in weight reduction and metabolic disease protocols.

Cagrilintide Dosage & Administration (Investigational Use)

No FDA‑approved prescribing information exists for cagrilintide or CagriSema at this time; all dosing insights come from clinical trial protocols and should be considered investigational, not therapeutic guidance.

Across phase 1-3 trials, cagrilintide is administered once weekly by subcutaneous injection, typically in the abdomen, thigh, or upper arm. Trials have generally used low starting doses (often 0.16-0.3 mg weekly) with gradual dose escalation in small steps over several weeks to months, up to target doses of 2.4 mg (monotherapy) or 2.4 mg in the CagriSema combination. This slow titration is designed to mitigate gastrointestinal intolerance (nausea, vomiting, early satiety).

The phase 1b combination study co‑escalated cagrilintide (0.16-4.5 mg) and semaglutide 2.4 mg every 4 weeks for 16 weeks, followed by a short maintenance period, while the phase 2 monotherapy trial used up to 6 weeks of dose escalation to reach each target weekly dose. Phase 3 programs for CagriSema and cagrilintide monotherapy use similar stepwise escalation schemes, but details vary by protocol and are not standardized for routine care.

Storage conditions in trials have typically included refrigeration at 2 to 8 °C, protection from light, and avoidance of freezing, consistent with handling of other peptide injectables.

Practitioners buying online should evaluate suppliers based on batch traceability, third-party purity verification, and storage handling documentation. Research institutions looking to buy cagrilintide wholesale for multi-site investigational programs can contact Medica Depot’s support representatives for support and documentation.

Legal Status of Cagrilintide

Regulatory status is dynamic; the summary below reflects publicly available information through May 2026 and should be re-verified against current regulatory databases before any protocol planning or evaluation of wholesale pricing.

• United States: As of May 2026, cagrilintide and the fixed-dose CagriSema combination are not approved by the FDA for therapeutic use. Novo Nordisk submitted an NDA for once‑weekly CagriSema (2.4 mg cagrilintide / 2.4 mg semaglutide) for chronic weight management in adults with obesity or overweight plus comorbidities in December 2025; review is ongoing and no approval decision has yet been announced.
• European Union: As of May 2026, neither cagrilintide monotherapy nor CagriSema has received marketing authorization from the EMA. Phase 3 REDEFINE trials include European sites, and regulatory submissions are anticipated after completion of the broader program, but no EMA decision has been published.
• Australia: The TGA has not approved cagrilintide or CagriSema for therapeutic use; these products remain investigational in Australia. Any use is currently restricted to clinical research under appropriate regulatory and ethics approvals.
• WADA: Cagrilintide is not currently listed on the WADA Prohibited List. Athletes and practitioners working in sport-adjacent contexts should independently verify current WADA guidance before any protocol consideration, as the Prohibited List is updated annually.

Cagrilintide Side Effects & Safety Profile

Across phase 1-3 studies, the safety profile of cagrilintide and CagriSema has been dominated by gastrointestinal and injection‑site adverse events, similar to other amylin‑ and incretin‑based therapies.

Gastrointestinal Symptoms

In the phase 2 monotherapy trial, 41–63% of cagrilintide‑treated participants reported GI events (vs 32% on placebo), primarily nausea, constipation, and diarrhea; these rates were broadly comparable to those with liraglutide 3.0 mg.

Phase 1b and later combination studies likewise show higher GI event rates with CagriSema than placebo, and higher rates than placebo in REDEFINE trials (e.g., ~80% vs ~40%), but generally mild–to‑moderate in severity.

Injection‑site Reactions

Transient injection‑site reactions (erythema, pruritus, mild discomfort) are commonly reported but usually self‑limited and rarely lead to discontinuation.

Cardiometabolic and Cardiovascular Safety

Across published phase 2 and interim phase 3 reports, no major cardiovascular safety signal has emerged, and overall adverse‑event‑related discontinuation rates have been in the same range as other incretin‑pathway drugs.

However, no dedicated large cardiovascular outcome trial (CVOT) for cagrilintide or CagriSema has yet been completed, so long‑term cardiovascular risk and benefit remain incompletely characterized.

Given the incomplete long‑term data, clinicians should frame all discussions of cagrilintide’s safety as provisional and tied to investigational use rather than established clinical practice.

Cagrilintide vs Semaglutide vs Tirzepatide vs Retatrutide

Compared with semaglutide, tirzepatide, and retatrutide, cagrilintide represents a distinct amylin-based approach to appetite regulation and the management of metabolic disease. Its complementary receptor mechanism is one reason cagrilintide and semaglutide combination therapy continues to attract clinical research interest.

Where Can Practitioners Buy Cagrilintide Online?

Cagrilintide is available for procurement exclusively by qualified professionals who are evaluating this investigational amylin analog for laboratory or clinical trial use. As an unapproved investigational compound in all major jurisdictions, sourcing should be limited to suppliers that provide verifiable purity documentation, certificate of analysis, LOT number traceability, and cold-chain compliance records. Medica Depot provides documentation guidance and procurement support for qualified professionals evaluating research-grade metabolic peptides.

Contact Medica Depot’s support representatives for guidance with sourcing documentation and to access available product references.

FAQs

1. What is cagrilintide and how does it work?

Cagrilintide is a long-acting amylin analog that activates amylin receptors in the brain to suppress appetite, slow gastric emptying, and reduce post-meal glucagon secretion. It is administered once weekly by subcutaneous injection and is currently being evaluated in Phase 3 trials for obesity and type 2 diabetes. It is investigational and not approved for routine prescribing.

2. How does cagrilintide compare to semaglutide?

Semaglutide targets GLP-1 receptors, while cagrilintide acts on amylin receptors involved in satiety signaling and appetite regulation through distinct pathways. Researchers are evaluating both together in the CagriSema program because their mechanisms may provide additive weight reduction effects. Semaglutide is FDA‑approved; cagrilintide, both as monotherapy and as part of the CagriSema combination, remains investigational and is not yet approved.

3. What weight loss can cagrilintide achieve?

Phase 2 monotherapy data showed a mean body‑weight reduction of about 10.8% over 26 weeks with once‑weekly cagrilintide 4.5 mg in adults with overweight/obesity receiving lifestyle counseling. Emerging phase 3 analyses suggest cagrilintide 2.4 mg monotherapy can produce roughly 11-12% weight loss at 68 weeks versus about 2-3% with placebo.

4. Is cagrilintide approved or available to prescribe?

Neither cagrilintide monotherapy nor the fixed‑dose cagrilintide/semaglutide combination (CagriSema) is approved by the FDA, EMA, TGA, or other major regulators for routine clinical use as of May 2026. CagriSema has completed pivotal phase 3 trials and filed an NDA with the FDA, but the application remains under review. Access is currently limited to clinical trials and research‑use supply channels, and these agents should not be described as prescribable options outside formal investigational frameworks.

5. What is the difference between cagrilintide and tirzepatide?

Tirzepatide is an approved once‑weekly dual GLP‑1/GIP receptor agonist with phase 3 obesity data demonstrating approximately 16-22.5% mean weight loss at 72 weeks in SURMOUNT‑1. Cagrilintide is a long‑acting amylin receptor agonist that targets multiple appetite‑regulation pathways via amylin/calcitonin receptor complexes and remains investigational, with both monotherapy and CagriSema combination programs in late‑phase development.

Citations

1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. doi:10.1016/S0140-6736(21)01751-7
2. D’Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2024;32(1):83-90. doi:10.1097/CRD.0000000000000513
3. Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide (RENEW 1). ClinicalTrials.gov identifier: NCT07220642. Updated April 08, 2026. https://clinicaltrials.gov/study/NCT07220642
4. National Center for Biotechnology Information. PubChem Compound Summary for CID 171397054, Cagrilintide. https://pubchem.ncbi.nlm.nih.gov/compound/Cagrilintide

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.